Overview
My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment. My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets. The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.
Current Duke Appointments & Affiliations
Associate Professor in Surgery
·
2023 - Present
Surgery, Surgical Sciences,
Surgery
Associate Professor in Pathology
·
2022 - Present
Pathology,
Clinical Science Departments
Associate Professor in Integrative Immunobiology
·
2023 - Present
Integrative Immunobiology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2020 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.
Journal article Mol Ther · July 1, 2026 Self-replicating RNA (srRNA) technology has received its first approval with Kostaive and Emergency Use Authorization for GEMCOVAC COVID-19 vaccines. The effective doses for srRNA vaccines are far lower than for conventional mRNA, as srRNA drives greater p ... Full text Link to item CiteEndogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy.
Journal article J Immunother Cancer · May 7, 2026 BACKGROUND: The contribution of B cells to antitumor immunity remains controversial, with studies reporting varied effects across cancer types. Even less is known about the role of the endogenous humoral response, including when tumor-elicited antibodies a ... Full text Link to item CiteDevelopment of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.
Preprint · April 24, 2026 BACKGROUND: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody-drug conjugates ... Full text Link to item CiteRecent Grants
Cell and Molecular Biology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2026 - 2031Genetics and Genomics Training Grant
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2026 - 2031Defining the role of TTK in neuroendocrine prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2031View All Grants
Education
Duke University ·
2006
Ph.D.